Double chin is a common problem that affects many middle aged people in Austin. Accumulation of fat tissue under the chin is what gives rise to a double chin. In the past, expensive surgical procedures were carried out to get rid of double chin like liposuction and Botox. Recent breakthrough for the treatment of double chin has emerged in the form of Kybella, a drug that has been approved by the Food and Drug Authority (FDA) for the treatment of double chin. It is a product of Kythera Biopharmaceuticals, Inc. that has minimal side effects and high success rate.
20 clinical trials were carried out to test its efficacy before Kybella was launched. More than 2,600 patient from around the globe participated in these pilot studies. Over 1600 of these patients were treated with Kybella for reducing the amount of fat under the chin. The figures that were obtained were staggering. 68.2 percent of the test subjects showed positive results and responded to treatment with Kybella. They reported a decreased amount of fat under the chin and an improved look.
Several side effects of the drug also came to light with these studies. Half of the subjects were given Kybella whereas the other half was given the placebo. 96% of the subjects who were given Kybella reported local injection site reactions (erythema, swelling, numbness, hematoma formation, induration, paresthesia, nodule formation, pruritus, skin tightness, nerve injury, local warmth). 8% of them complained of headache. About 3% of them gave an account of oropharyngeal pain. 2% of them reported nausea and another 2% recounted difficulty in swallowing.
No reliable data is available that supports Kybella as being safe for use in pregnant women and lactating mothers. It has, as yet, not been established for use in children less than 18 years of age and in older population above 65 years. Further trials need to be carried out before Kybella can be declared safe for use in these specific populations.
Two randomized controlled, double blinded trials were held to assess the efficacy of Kybella for the treatment of double chin in population aged 19 to 65. Significant reduction in the amount of submental fat was observed in subjects who were given Kybella as compared to those who were given the placebo. These trials, thus, ascertained the effectiveness of Kybella in decreasing the submental convexity and enhancing the overall appearance.